Accéder au contenu
Merck

Manipulations of MeCP2 in glutamatergic neurons highlight their contributions to Rett and other neurological disorders.

eLife (2016-06-22)
Xiangling Meng, Wei Wang, Hui Lu, Ling-Jie He, Wu Chen, Eugene S Chao, Marta L Fiorotto, Bin Tang, Jose A Herrera, Michelle L Seymour, Jeffrey L Neul, Fred A Pereira, Jianrong Tang, Mingshan Xue, Huda Y Zoghbi
RÉSUMÉ

Many postnatal onset neurological disorders such as autism spectrum disorders (ASDs) and intellectual disability are thought to arise largely from disruption of excitatory/inhibitory homeostasis. Although mouse models of Rett syndrome (RTT), a postnatal neurological disorder caused by loss-of-function mutations in MECP2, display impaired excitatory neurotransmission, the RTT phenotype can be largely reproduced in mice simply by removing MeCP2 from inhibitory GABAergic neurons. To determine what role excitatory signaling impairment might play in RTT pathogenesis, we generated conditional mouse models with Mecp2 either removed from or expressed solely in glutamatergic neurons. MeCP2 deficiency in glutamatergic neurons leads to early lethality, obesity, tremor, altered anxiety-like behaviors, and impaired acoustic startle response, which is distinct from the phenotype of mice lacking MeCP2 only in inhibitory neurons. These findings reveal a role for excitatory signaling impairment in specific neurobehavioral abnormalities shared by RTT and other postnatal neurological disorders.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-MeCP2 antibody, Mouse monoclonal, clone Mec-168, purified from hybridoma cell culture